Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

HTTPS

Secure .gov websites use HTTPS
A lock (LockA locked padlock) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • About HHS
  • MAHA in Action
  • Programs & Services
  • Grants & Contracts
  • Laws & Regulations
  • Radical Transparency
Breadcrumb
  1. Home
  2. Press Room
  3. Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research
  • Press Room
  • HHS Live
FOR IMMEDIATE RELEASE
November 11, 2025
Contact: HHS Press Office
202-690-6343
Submit a Request for Comment

Longtime FDA Innovator Appointed as Director of Center for Drug Evaluation and Research

WASHINGTON—NOVEMBER 11, 2025—The U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) today announced that Richard Pazdur, M.D., has been appointed director of the Center for Drug Evaluation and Research (CDER). Pazdur is a 26-year veteran of the FDA and the founding director of its Oncology Center of Excellence.

A renowned regulatory innovator, Dr. Pazdur developed an integrated approach for cross-center coordination of oncology product review to expedite the development of novel cancer therapies. He also led the agency's launch of a series of initiatives that streamlined oncology drug approvals, access, and labeling: Project Orbis to provide a framework for concurrent submission and review of oncology products among international partners, Project Facilitate to support oncology professionals in completing expanded access requests for cancer patients, and Project Renewal to update the prescribing information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date.

“Dr. Pazdur is a true regulatory innovator who will help guide our broader agenda to modernize the agency and streamline the approval process,” said FDA Commissioner Marty Makary, M.D., M.P.H. “He has a track record of success and is an impressive forward-thinking scientist.”

“I’m honored to lead CDER at a time when the FDA is achieving long-sought regulatory reforms,” said Dr. Pazdur. “I look forward to working closely with Dr. Makary and the medical experts he’s assembled to help our country reach its peak in drug development.”

Before joining the FDA, Dr. Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. He received his bachelor’s degree from Northwestern University, his M.D. from Loyola Stritch School of Medicine, and completed clinical training at Rush-Presbyterian St. Luke’s Medical Center and the University of Chicago Hospitals and Clinics. Dr. Pazdur has published more than 800 articles, book chapters, and abstracts, and two medical oncology textbooks.

Dr. Pazdur will continue to serve as director of the Oncology Center of Excellence until a successor is named.

###
Note: All HHS press releases, fact sheets and other news materials are available in our Press Room.
Like HHS on Facebook, follow HHS on X @HHSgov, @SecKennedy, and sign up for HHS Email Updates.
Last revised: November 11, 2025

Submit a request for comment

For media inquiries, please submit a request for comment.

Sign up to receive our press releases

Sign Up

Related Press Releases

  • Secretary Kennedy Swears in Dr. Anthony Letai as Director of the National Cancer Institute

    • September 29, 2025 Press Release
Content created by Assistant Secretary for Public Affairs (ASPA)
Content last reviewed November 11, 2025
Back to top
Secretary Robert F. Kennedy Jr.

Follow @SecKennedy

HHS icon

Follow @HHSGov

HHS Email updates

Receive email updates from HHS.

Subscribe

HHS Logo

HHS Headquarters

200 Independence Avenue, S.W.
Washington, D.C. 20201
Toll Free Call Center: 1-877-696-6775​

  • Contact HHS
  • Careers
  • HHS FAQs
  • Nondiscrimination Notice
  • Press Room
  • HHS Archive
  • Accessibility Statement
  • Privacy Policy
  • Budget/Performance
  • Inspector General
  • Web Site Disclaimers
  • EEO/No Fear Act
  • FOIA
  • The White House
  • USA.gov
  • Vulnerability Disclosure Policy